Abiomed, Inc. (ABMD)
Stock Price:
$265.25 USD
-2.96 (-1.10%)
Updated December 2, 4:00 PM EST - Market closed
Key Info
| Market Cap |
11.99B |
| Revenue (ttm) |
802.86M |
| Net Income (ttm) |
207.82M |
| Shares Out |
45.10M |
| EPS (ttm) |
4.55 |
| PE Ratio |
58.30 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 2 |
| Last Price |
$265.25 |
| Previous Close |
$268.21 |
| Change ($) |
-2.96 |
| Change (%) |
-1.10% |
| Day's Open |
268.22 |
| Day's Range |
263.76 - 268.22 |
| Day's Volume |
169,002 |
| 52-Week Range |
130.51 - 317.00 |
More Stats
| Market Cap |
11.99B |
| Enterprise Value |
11.45B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
45.10M |
| Float |
n/a |
| EPS (basic) |
4.60 |
| EPS (diluted) |
4.55 |
| FCF / Share |
5.46 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
1.72% |
| FCF Yield |
2.05% |
| Payout Ratio |
n/a |
| Shares Short |
2.05M |
| Short Ratio |
6.78 |
| Short % of Float |
n/a |
| Beta |
1.43 |
| PE Ratio |
58.30 |
| Forward PE |
n/a |
| P/FCF Ratio |
48.72 |
| PS Ratio |
14.93 |
| PB Ratio |
10.39 |
| Revenue |
802.86M |
| Operating Income |
223.71M |
| Net Income |
207.82M |
| Free Cash Flow |
246.05M |
| Net Cash |
533.08M |
| Net Cash / Share |
11.80 |
| Gross Margin |
85.89% |
| Operating Margin |
27.86% |
| Profit Margin |
25.90% |
| FCF Margin |
30.65% |
| ROA |
11.49% |
| ROE |
19.12% |
| ROIC |
30.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (9)
| Buy |
4 |
| Overweight |
0 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$312.40*
(17.78% upside)
Low
217
Current: $265.25
High
365
Target: 312.40
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 841 | 769 | 594 | 445 | 330 | 230 | 184 | 158 | 126 | 101 |
| Revenue Growth | 9.29% | 29.59% | 33.34% | 35.13% | 43.09% | 25.41% | 16.14% | 25.12% | 24.94% | - |
| Gross Profit | 690 | 640 | 495 | 375 | 279 | 190 | 146 | 127 | 102 | 79.17 |
| Operating Income | 249 | 225 | 157 | 90.14 | 65.10 | 28.67 | 8.36 | 16.54 | 1.52 | -11.19 |
| Net Income | 203 | 259 | 112 | 52.12 | 38.15 | 114 | 7.35 | 15.01 | 1.50 | -11.76 |
| Shares Outstanding | 45.18 | 44.91 | 44.15 | 43.24 | 42.20 | 40.63 | 39.33 | 39.11 | 38.37 | 37.17 |
| Earnings Per Share | 4.43 | 5.61 | 2.45 | 1.17 | 0.85 | 2.65 | 0.18 | 0.37 | 0.04 | -0.32 |
| EPS Growth | -21.03% | 128.98% | 109.4% | 37.65% | -67.92% | 1372.22% | -51.35% | 825% | - | - |
| Operating Cash Flow | 315 | 252 | 193 | 115 | 76.80 | 43.29 | 23.47 | 26.40 | 3.63 | 1.57 |
| Capital Expenditures | -44.01 | -44.00 | -55.86 | -50.42 | -15.62 | -5.19 | -2.76 | -2.84 | -1.75 | -1.80 |
| Free Cash Flow | 271 | 208 | 137 | 64.70 | 61.17 | 38.10 | 20.71 | 23.56 | 1.89 | -0.23 |
| Cash & Equivalents | 443 | 492 | 362 | 230 | 212 | 132 | 76.58 | 76.71 | 77.22 | 60.31 |
| Total Debt | - | - | - | 16.34 | - | - | - | - | - | - |
| Net Cash / Debt | 443 | 492 | 362 | 214 | 212 | 132 | 76.58 | 76.71 | 77.22 | 60.31 |
| Assets | 1,216 | 1,054 | 786 | 550 | 424 | 338 | 205 | 170 | 154 | 132 |
| Liabilities | 151 | 117 | 96.85 | 98.34 | 55.16 | 46.81 | 37.05 | 32.92 | 27.61 | 26.85 |
| Book Value | 1,065 | 937 | 690 | 452 | 369 | 292 | 168 | 137 | 126 | 105 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Abiomed, Inc. |
| Country |
United States |
| Employees |
1,536 |
| CEO |
Michael Minogue |
Stock Information
| Ticker Symbol |
ABMD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: ABMD |
| IPO Date |
July 29, 1987 |
Description
Abiomed engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.